Compare · BSX vs SONX
BSX vs SONX
Side-by-side comparison of Boston Scientific Corporation (BSX) and Sonendo Inc. (SONX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SONX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 375.4x SONX ($192.5M).
- BSX has hit the wire 11 times in the past 4 weeks while SONX has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 6 for SONX).
- Company
- Boston Scientific Corporation
- Sonendo Inc.
- Price
- -
- -
- Market cap
- $72.26B
- $192.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 6
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Sonendo Inc.
Sonendo, Inc. develops, manufactures, and sells devices for root canal therapy in the United States and Canada. It offers GentleWave, a device to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. Sonendo, Inc. was incorporated in 2006 and is based in Laguna Hills, California.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
Latest SONX
- Amendment: SEC Form SCHEDULE 13G/A filed by Sonendo Inc.
- Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
- Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance
- Sonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial Guidance
- SEC Form D filed by Sonendo Inc.
- Sonendo, Inc. Announces $5.0 Million Private Placement
- SEC Form 10-K filed by Sonendo Inc.
- Sonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
- SEC Form EFFECT filed by Sonendo Inc.
- SEC Form EFFECT filed by Sonendo Inc.